Ajaypal Singh to United States
This is a "connection" page, showing publications Ajaypal Singh has written about United States.
Connection Strength
0.471
-
Message to the FDA on ESAs: REMS is not enough, more studies are needed. Clin J Am Soc Nephrol. 2010 Aug; 5(8):1355-8.
Score: 0.055
-
The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis. Clin J Am Soc Nephrol. 2010 Apr; 5(4):553-6.
Score: 0.054
-
Should we keep hemoglobin levels as a viable outcome measure? Nephrol News Issues. 2010 Mar; 24(3):15-6, 18.
Score: 0.054
-
The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Am J Kidney Dis. 2008 Dec; 52(6 Suppl):S5-13.
Score: 0.049
-
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation. Kidney Int. 2008 Dec; 74(12):1588-95.
Score: 0.049
-
Is it time to reconsider subcutaneous administration of epoetin? Nephrol News Issues. 2007 Oct; 21(11):57, 59, 63-4 passim.
Score: 0.045
-
Anemia of chronic kidney disease: CHOIR and the FDA. Nat Clin Pract Nephrol. 2007 Aug; 3(8):406-7.
Score: 0.045
-
The FDA black box for EPO: what should nephrologists do? Nephrol News Issues. 2007 May; 21(6):55-6, 58-9.
Score: 0.044
-
Outcomes of renal transplantation for recipients with lupus nephritis: analysis of the Organ Procurement and Transplantation Network database. Transplantation. 2006 Sep 15; 82(5):612-8.
Score: 0.042
-
A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. Am J Nephrol. 2017; 46(5):364-370.
Score: 0.023
-
Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol. 2007 Dec; 18(12):3184-91.
Score: 0.011